• Company
• Whether Ilaris for 10 will receive reimb gains attention
• by Eo, Yun-Ho Nov 8, 2023 05:37am

• Policy
• A draft for reevaluation of overseas drug prices
• by Lee, Tak-Sun Nov 8, 2023 05:37am

• Company
• Budesonide’s price to be raised due to increased demand
• by Chon, Seung-Hyun Nov 7, 2023 05:34am

• Policy
• Drug price reduction delayed due to suspension of execution
• by Lee, Jeong-Hwan Nov 7, 2023 05:34am

• Company
• Chong Kun Dang signs KRW 1.7 tril deal with Novartis
• by Kim, Jin-Gu Nov 7, 2023 05:34am

• Opinion
• [Reporter's view] Preferential pharmaceutical alternative
• by Lee, Jeong-Hwan Nov 7, 2023 05:34am

• Company
• First GIFT drug Lunsumio in reimb process after approval
• by Eo, Yun-Ho Nov 7, 2023 05:33am

• Policy
• Lunsumio receives marketing authorization in Korea
• by Lee, Hye-Kyung Nov 6, 2023 05:27am

• Company
• Scemblix may be prescribed at Big 5 Hospitals in KOR
• by Eo, Yun-Ho Nov 6, 2023 05:27am

• Company
• Wegovy and Mounjaro begin to dominate the obesity market
• by Kim, Jin-Gu Nov 6, 2023 05:27am